Patients are encouraging the US FDA to consider treatments allowing control or management of opioid use, rather than seeking complete abstinence, may be a laudable goal for opioid use disorder.
A significant portion of FDA's April 17 patient-focused drug development meeting on opioid use disorder included discussion of potential medications not designed to achieve abstinence from opioid use
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?